hrcak mascot   Srce   HID

ADMET and DMPK, Vol.6 No.1 Ožujak 2018.

Pregledni rad
https://doi.org/10.5599/admet.6.1.496

The role of pharmacology in anticancer drug development

Godefridus Peters   ORCID icon orcid.org/0000-0002-5447-2877 ; Dept of Medical Oncology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
Anne-Sophie Govaerts ; EORTC, Avenue E. Mounier 83/11, 1200 Brussels, Belgium
Hans Hendriks   ORCID icon orcid.org/0000-0003-1109-4615 ; Hendriks Pharmaceutical Consulting, J. Wagenaarstraat 67, 1443 LR Purmerend, The Netherlands
for the EORTC- Pharmacology and Molecular Mechanism Group ; EORTC, Avenue E. Mounier 83/11, 1200 Brussels, Belgium

Puni tekst: engleski, pdf (910 KB) str. 4-14 preuzimanja: 50* citiraj
APA 6th Edition
Peters, G., Govaerts, A., Hendriks, H. i Molecular Mechanism Group, f.t.E.P.a. (2018). The role of pharmacology in anticancer drug development. ADMET and DMPK, 6 (1), 4-14. https://doi.org/10.5599/admet.6.1.496
MLA 8th Edition
Peters, Godefridus, et al. "The role of pharmacology in anticancer drug development." ADMET and DMPK, vol. 6, br. 1, 2018, str. 4-14. https://doi.org/10.5599/admet.6.1.496. Citirano 19.08.2018.
Chicago 17th Edition
Peters, Godefridus, Anne-Sophie Govaerts, Hans Hendriks i for the EORTC- Pharmacology and Molecular Mechanism Group. "The role of pharmacology in anticancer drug development." ADMET and DMPK 6, br. 1 (2018): 4-14. https://doi.org/10.5599/admet.6.1.496
Harvard
Peters, G., et al. (2018). 'The role of pharmacology in anticancer drug development', ADMET and DMPK, 6(1), str. 4-14. doi: https://doi.org/10.5599/admet.6.1.496
Vancouver
Peters G, Govaerts A, Hendriks H, Molecular Mechanism Group ftEPa. The role of pharmacology in anticancer drug development. ADMET and DMPK [Internet]. 25.03.2018. [pristupljeno 19.08.2018.];6(1):4-14. doi: https://doi.org/10.5599/admet.6.1.496
IEEE
G. Peters, A. Govaerts, H. Hendriks i f.t.E.P.a. Molecular Mechanism Group, "The role of pharmacology in anticancer drug development", ADMET and DMPK, vol.6, br. 1, str. 4-14, Kolovoz 2018. [Online]. doi: https://doi.org/10.5599/admet.6.1.496

Sažetak
Drug development consists of many sequential and parallel steps; failure in one of the steps can lead to discontinuation of the process. The process is time-consuming and very expensive, especially the clinical phase. In order to enhance cancer drug development in the 1980s, the National Cancer Institute (NCI) adopted a new screening system using 60 different tumour cell lines from various histologies. All standard drugs were tested in this panel and it is still open for testing of new chemical entities (NCE) of potential interest. The European NCI compounds initiative, a collaborative programme of the NCI, the Cancer Research Campaign (CRC; now CRUK) and the Pharmacology and Molecular Mechanism Group (PAMM) of the EORTC (European Organization on Research and Treatment of Cancer), was initiated in 1993. The programme aimed to help the NCI reducing its backlog of in vivo testing by further evaluation of interesting European compounds using a pharmacologically directed approach. Considerable multidisciplinary expertise in drug development was combined by the CRC and EORTC-PAMM: chemists, pharmacists, biologists, pharmacologists, oncologists. Selection criteria for European NCI compounds included novelty of the NCE, in vitro activity, if available in vivo and hollow fibre activity, and COMPARE negativity. Over a period of more than 20 years 95 out of approximately 2,000 reviewed compounds were selected. These compounds were put through a series of stepwise pharmacological tests comprising solubility (suitable formulation to administer the NCE to mice), feasibility to develop a simple analytical assay (usually HPLC), limited toxicology and angiogenic properties. This paper provides examples to illustrate the rigorousness of the elimination process of the compounds and discusses the way to improve the process by inclusion of more physico-chemical parameters.

Ključne riječi
EORTC-PAMM; NCI; CRUK; in vitro screen; pharmacological approach; anticancer drug development; European NCI compounds

Hrčak ID: 196397

URI
https://hrcak.srce.hr/196397

Posjeta: 80 *